About Karma Biotechnologies
Karma Biotechnologies is a Los Angeles startup dedicated to solving autoimmunity, allergies, and food sensitivities with our Xavine™ precision immunotherapy platform. General immune suppression is still the standard of care for most autoimmune disease patients; there is a critical unmet need to develop antigen-specific therapies that inhibit only the disease-causing rogue immune cells. To meet this need, Karma is leveraging expertise in immunology and lipid nanoparticle engineering to develop tolerogenic immunotherapies that elicit antigen-specific immune tolerance in vivo.
Company details
Funding
Total raised
$5.0M
Last stage
Seed
Investors
Founders
Andrew Gray
Co-Founder and CEO of Karma Biotechnologies; previously co-founded Vali Nanomedical and participated in IndieBio SF Batch 2.
Alan Johnson
Co-Founder and COO of Karma Biotechnologies; long-time collaborator of Andrew Gray, previously co-founded Vali Nanomedical.
Don Johnson
Co-founder and Director at Karma Biotechnologies.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.